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Background: Surveillance of antimicrobial resistance (AMR) is critical to reducing its wide-reaching impact. Its re-
liance on sample size invites solutions to longstanding constraints regarding scalability. A robotic platform
(RASP) was developed for high-throughput AMR surveillance in accordance with internationally recognized
standards (CLSI and ISO 20776-1:2019) and validated through a series of experiments.
Methods: Experiment A compared RASP’s ability to achieve consistent MICs with that of a human technician
across eight replicates for four Escherichia coli isolates. Experiment B assessed RASP’s agreement with human-
performed MICs across 91 E. coli isolates with a diverse range of AMR profiles. Additionally, to demonstrate its
real-world applicability, the RASP workflow was then applied to five faecal samples where a minimum of 47
E. coli per animal (239 total) were evaluated using an AMR indexing framework.
Results: For each drug–rater–isolate combination in Experiment A, there was a clear consensus of the MIC and
deviation from the consensus remained within one doubling dilution (the exception being gentamicin at two
dilutions). Experiment B revealed a concordance correlation coefficient of 0.9670 (95% CI: 0.9670–0.9670)
between the robot- and human-performed MICs. RASP’s application to the five faecal samples highlighted the
intra-animal diversity of gut commensal E. coli, identifying between five and nine unique isolate AMR phenotypes
per sample.
Conclusions: While adhering to internationally accepted guidelines, RASP was superior in throughput, cost
and data resolution when compared with an experienced human technician. Integration of robotics platforms in
the microbiology laboratory is a necessary advancement for future One Health AMR endeavours.
Introduction
Antimicrobial resistance (AMR) has been described as one of the
greatest threats to global health and food security, with an esti-
mated cumulative cost of 100 trillion USD by 2050.1 The major
consequence of resistance is the escalating difficulty of successful-
ly treating bacterial infections with the currently available limited
array of antimicrobials. We now face the risk of returning to the
pre-antibiotic era where bacterial infections in humans and
animals were a major cause of mortality.2 Preserving the useful-
ness of existing antimicrobials by reducing selection and limiting
the dissemination of resistant organisms is therefore a high prior-
ity. Consequently, a key component of management efforts is sur-
veillance designed to keep authorities and clinicians aware of
where and when resistance is present and evolving.3 Surveillance
of AMR faces many challenges owing to the multi-host, multi-
pathogen, multi-drug nature of the resistance phenomenon.
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Perhaps one of the most problematic aspects is the insidious na-
ture of resistance—it emerges slowly without necessarily yielding
expression of any outward signs and frequently has an impact at a
place and time other than its origin. For surveillance to overcome
these obstacles, careful attention needs to be paid to the choice of
pairing of assays for measuring resistance in bacteria and the de-
sign of sample acquisition from animals, food and the
environment.
Surveillance for AMR in animals and food is a well-established ac-
tivity. The WHO has longstanding recommendations for the conduct
of ‘integrated surveillance’, as part of the multifaceted manage-
ment for the control of resistance.4 Countries such as Denmark5 and
the USA6 have been at the forefront of surveillance for AMR in ani-
mals and the food chain with programmes running since as early as
1995. Since then, the basic approach in food animals, which is now
widely adopted throughout the developed world, has changed very
little. A core component is the collection and analysis of data relat-
ing to the AMR profile of indicator bacteria (such as Escherichia coli)
from various livestock and commodities.7 As a result of the high cost
per isolate (of which laboratory processing contributes a significant
portion), most national-level surveys typically only collect data
on approximately 150–250 individually selected isolates per year
from each livestock sector. While the resulting data provide a gen-
eral overview on AMR in food animals, the inferences that can be
drawn are limited. In addition, recent data have demonstrated
variation of E. coli resistance profiles within bacterial species from
the same host,8 suggesting that reliable estimates of AMR require
the collection of multiple isolates from a single host.
In order to effectively limit the emergence and spread of AMR
within groupings of animals or humans, surveillance data must be
strengthened to make it more relevant to antimicrobial steward-
ship.9 A paramount need is for the individuals responsible for anti-
microbial stewardship in a setting to receive intelligence from
surveillance describing the occurrence of resistance. To deliver
such feedback, epidemiologically appropriate study design and
sample size needs to be combined with cost-effective character-
ization of much larger numbers of bacteria than are currently eval-
uated.10 At present, the isolation of large numbers of bacterial
colonies, subsequent antimicrobial susceptibility testing (AST) with
traditional techniques and genomic characterization is not only
cost prohibitive but a severe drain on time and resources. Scaling
up traditional methods is unattractive because it would inevitably
introduce inaccuracy arising from fatigue of laboratory workers.
However, the harnessing of high-throughput laboratory robotic
platforms capable of handling individual colonies on an unprece-
dented scale and without the loss of accuracy from fatigue we
associate with manual methods is a practical solution.
In this study, we describe the development of the next-
generation approach to surveillance for AMR using a Robotic
Antimicrobial Susceptibility Platform (RASP) and demonstrate that
the RASP method is elegantly and efficiently adapted to high-
volume surveillance of commensal organisms. The system auto-
mates the process of bacterial isolation, identification (with or
without reliance on spectrography) and AST for customized combi-
nations of drugs. With this comes a much-needed improvement in
the ability to design surveillance to meet objectives that are of
practical relevance at the coalface of antimicrobial stewardship.
Methods
System overview
RASP was developed to assess phenotypic resistance in a manner compar-
able with major surveillance programmes. Unlike other approaches to
‘scaling up’ such as metagenomics, RASP keeps the nucleic acid of individual
isolates available for study, making it possible to understand if resistance is
mediated by previously unidentified genes while avoiding biases due to the
presence of extraneous nucleic acid from environmental organisms.
RASP is a customizable robotics platform that was designed, using avail-
able Tecan (Switzerland) and SciRobotics Ltd (Israel) products, to be flexible
and multifunctional, capable of bacterial isolation, isolate collection, prep-
aration for identification and AST. A Tecan Freedom EVOV
R
150 base was
combined with the SciRobotics carousel capable of holding both Petri dishes
and 96-well microplates. SciRobotics equipment was incorporated into the
robot deck, the PetriPlaterTM to dispense samples and PickoloTM software
using image analysis to select colonies, in addition to a microplate absorb-
ance reader for AST inoculum adjustment to deliver high-throughput
surveillance (Figure S1, available as Supplementary data at JAC Online).
The robot has also been fully integrated with barcoding capabilities to track
isolates from original source to phenotypic results and is integrable with
any electronic laboratory information management system. The general
workflow for this method is visualized in Figure 1 and the major steps
detailed below. Homogenized samples are loaded onto the robot in a liquid
format and either serially diluted or directly streaked onto agar. After incu-
bation individual colonies are selected using PickoloTM, based on the explicit
requirements of the user, including colour, size and morphology. Individual
colonies are transferred to a 96-well microplate and a deep-well plate in
preparation for AST and isolate storage, respectively. MALDI-TOF identifica-
tion can also be performed at this timepoint and, as such, the robot includes
a position for a MALDI-TOF target plate and is capable of both sample and
matrix addition. AST is then performed using an entirely liquid-based meth-
odology adapted for the RASP platform from internationally established
guidelines: CLSI11 and ISO 20776-1:2019; including compliance to quality
control criteria. AST drug panels, genotyping and WGS can be prepared
using the Freedom EVO genomics platform. While the above workflow was
well suited to this current study, it should be noted that it represents one
of many possibilities. RASP workflows are flexible and, due to the modular
design of hardware, can be adjusted to suit different bacterial species,
sample types, culture media and drug panels.
Bacterial isolation
Two grams of faecal sample was homogenized in 18 mL PBS. Homogenized
samples then underwent four 10-fold serial dilutions and were plated onto
CHROMagarTM ECC (Edwards, MM1076) using the two-zone spiral plating
protocol at 10#3 (outer zone) and 10#4 (inner zone) (Video S1). After over-
night incubation at 37C, PickoloTM colony picking software was used to tar-
get and pick up to 48 presumptive E. coli colonies per plate based on their
adherence to previously determined colour, size and circularity criteria
(Video S2) and transferred to 96-well plates containing CAMHB (BD,
212322) for overnight growth at 37C for storage and subsequent assays.
Bacterial identification
Isolates were prepared for MALDI-TOF identification by adding 40lL of
90% formic acid to the bacterial pellet from overnight culture (Video S3).
Species identification was then performed by MALDI-TOF adhering to man-
ufacturer’s protocol (Bruker MALDI Biotyper Microflex LT/SH MALDI-MS
running MBT Compass 4.1 Build 70 and flexControl 3.4 Build 135).
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AST
All isolates were grown from storage at –80C onto sheep blood agar
(Edwards, MM1120) overnight at 37C. A second subculture was performed
the following day, and the workflow diverged depending on the prospective
rater.
RASP platform
Isolates intended for robot-performed susceptibility testing were subcul-
tured in a flat-bottom 96-well plate (Nunc, 167008), each well filled with
220 lL (allowing for overnight evaporation of roughly 20 lL) CAMHB (BD,
212322). The robot protocol adjusted isolates from the overnight broth cul-
ture using an absorbance reader at 620 nm wavelength to an absorbance
equivalent to a McFarland standard (0.08 to 0.13). The McFarland standar-
dized isolate was transferred to a deep-well plate and diluted 1:20 in sterile
water, and the drug plate was inoculated with 10 lL of isolate in 90 lL of
CAMHB-diluted drug (Video S4). For colony enumeration, the robot per-
formed further dilutions (1:150 followed by another 1:150) on the previous-
ly diluted McFarland standard and plated 100 lL on sheep blood agar using
a modification of the two-zone spiral dilution plating method; whereby the
entire plate is inoculated as just one zone (lawn plating). Following an over-
night incubation (16–20 h at 37C as per CLSI guidelines), drug plate results
for both raters were read using the Sensititre Vizion plate reader system,
and colony enumeration on sheep blood agar was performed and recorded
using the PickoloTM colony counting software.
Human technician
Isolates intended for human-performed susceptibility testing were sub-
cultured on sheep blood agar. The human broth microdilution protocol
followed CLSI guidelines, with the adjustment of isolates to a 0.5
McFarland standard using a nephelometer (SensititreTM), followed by a
1:100 dilution in CAMHB prior to inoculation of the drug plate using
Sensititre’s AIMTM automated inoculation delivery system (50 lL inocu-
lum into 50 lL of drug diluted in CAMHB). The colony enumeration qual-
ity control step was performed for each isolate on sheep blood agar as
per CLSI guidelines with a 1:1000 dilution of inoculum in 0.9% saline and
lawn plating on agar.
Validation and application of RASP
To evaluate the capacity of the robot and validate its use in AST, we applied
the RASP robotic platform to the aforementioned workflow using a collec-
tion of E. coli because E. coli is an ideal indicator organism and represents
a ubiquitous component of surveillance for AMR in animals.5,6,12
AST validation Experiment A: assessment of
repeatability
An experiment was conducted to validate the RASP platform’s AST protocol
by comparing the ability of both human and robot rater to generate consist-
ent MICs across replicates. Each rater performed AST on four E. coli isolates
in octuplicate against the following antimicrobials: ampicillin, cefoxitin,
ceftiofur, chloramphenicol, ciprofloxacin, colistin, ceftriaxone, florfenicol,
gentamicin, streptomycin, trimethoprim/sulfamethoxazole, and tetracyc-
line. Isolates were derived from various sources including an American
Type Culture Collection 25922, and one isolate of seagull,13 porcine14 and
cattle origin,15 each with previously determined AMR profiles.
AST validation Experiment B: assessment of rater
agreeance
Experiment B was a breadth study whereby the RASP platform and an
experienced human technician performed AST on a diverse range of iso-
lates (n = 91) with varying, previously characterized AMR profiles and host
origins (seagull, porcine, cattle).13–17 The RASP platform was assessed
based on its agreeance with the human technician in their determination
of MICs for each isolate. Antimicrobials tested included: ampicillin,
cefoxitin, ceftiofur, chloramphenicol, ciprofloxacin, colistin, ceftriaxone, flor-
fenicol, gentamicin, streptomycin, trimethoprim/sulfamethoxazole, and
tetracycline.
RASP workflow application: antimicrobial resistance
surveillance index scoring
To demonstrate the level of resolution achievable with RASP, five faecal
samples were collected from pig pen floors (one sample per pen) and pro-
ceeded through the RASP workflow described above to yield AST data for
239 derivative E. coli isolates (minimum to 47 per sample) against six anti-
microbials (ampicillin, ceftiofur, ciprofloxacin, gentamicin, tetracycline and
trimethoprim/sulfamethoxazole). A secondary classification and visualiza-
tion script devised in Stata18 was applied to the 239 isolates to generate a
graphical representation of intra-animal and intra-herd diversity, as well as
to assign an index score representative of the threat posed by their
Figure 1. Overview of a typical RASP workflow. Any processes depicted
outside the border occur externally to RASP. This figure appears in colour
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AMR burden. The indexing scheme assigned weights (w) to antimicrobials
informed by national19 and international20 guidelines whereby the anti-
microbials deemed more important to human health received a
higher weighting. Antimicrobial weights were as follows: ampicillin (w = 1),
ceftiofur (w = 3), ciprofloxacin (w = 4), gentamicin (w = 2), tetracycline (w = 1),
and trimethoprim/sulfamethoxazole (w = 2). In this study, the maximum
possible AMR score was 13, indicating resistance to all tested antimicrobials.
Throughput comparison analysis
An analytical component of this study sought to compare the time
required by a human technician utilizing current methods, versus a
robot-assisted technician, to process 20 homogenized faecal samples
(deriving 960 isolates) from isolation through to phenotypic character-
ization. A simulated workflow was developed for each technician based
on average times taken to perform each task within the workflow and
applied to the above scenario. The human technician was allowed the
use of ‘modern’ laboratory implements such as Sensititre’s auto-inocu-
lator and Vizion plate reader systems, pre-ordered ready-to-use drug
plates and a MALDI-TOF, while the robot-assisted technician had the
two previously discussed Tecan robots, a MALDI-TOF and a Sensititre
Vizion plate reader system at their disposal.
Results
AST validation Experiment A: assessment of
repeatability
In Experiment A, when comparing the human (H) and robot (R)
MIC results for each isolate, the mode MIC for an isolate across
both raters against a specific antimicrobial was labelled the ‘con-
sensus MIC’ and any deviation from the consensus MIC deemed a
Figure 2. Experiment A: comparison of human (‘H’) and robot (‘R’) MIC results for four fully susceptible E. coli isolates each replicated eight times per
rater, tested against a panel of antimicrobials. Each isolate–rater designation displays the MIC results for all eight replicates of that combination.
Antimicrobials: AMP, ampicillin; CIP, ciprofloxacin; GEN, gentamicin; TET, tetracycline. This figure appears in colour in the online version of JAC and in
black and white in the print version of JAC.
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departure from the truest result (Figure 2). Of the drug–rater–anti-
microbial combinations tested (see Figure S2 for all combinations),
the majority showed all eight replicates having achieved the same
MIC result, and furthermore demonstrate agreeance between the
two raters; all isolates and replicates tested against tetracycline
achieved the same MIC between both isolate and rater. Of the
cases where deviation from the consensus MIC was seen, it was
limited to one doubling dilution (the exception being gentamicin at
two dilutions) and there remained moderate agreement between
the two raters, with similar distributions of replicates across MIC
results.
AST validation Experiment B: assessment of rater
agreement
In Experiment B, the majority of combinations of isolates and
drugs (67.6%) tested showed complete agreement between the
two human and robot raters while 23.4% had a discrepancy in MIC
result by one, which is acceptable according to international guide-
lines, and 9.0% had a discrepancy of two or more doubling dilu-
tions (Figure 3). The greatest discrepancy in MIC between raters
was a difference of nine dilutions between the two results and rep-
resented 0.26% of the isolate–drug combinations tested. The over-
all agreement for isolate–drug combinations between robot and
human was summarized by a concordance correlation coefficient
of 0.9670 (95% CI: 0.9670–0.9670), N = 1092.
RASP workflow application: antimicrobial resistance
surveillance index scoring
All homogenized faecal samples that were plated by RASP on
CHROMagarTM ECC selective agars yielded growth of at least 48 sin-
gle colonies matching the expected blue appearance of E. coli at
one or both dilutions. Isolates were successfully identified as E. coli
using RASP’s MALDI-TOF preparation protocol, all with high identifi-
cation scores; the lowest identification score achieved was 2.2,
which qualified within Bruker’s highest confidence range.
Samples from all animals exhibited a diverse range of AMR pro-
files amongst isolates, including resistance to antimicrobials tested
(Figure 4). All animals, except one, had isolates representing an
AMR index of zero. The highest AMR index recorded was 13, com-
prising resistance to all tested antimicrobials. A relatively balanced
Figure 3. Experiment B: paired MIC results on 96 isolates with 12 drugs directly comparing human and robot measurements. Marker size represents
proportion of paired observations for the isolate–drug combination. Antimicrobials: AMP, ampicillin; FOX, cefoxitin; CFT, ceftiofur; CHL, chlorampheni-
col; CIP, ciprofloxacin; CST, colistin; CRO, ceftriaxone; FLO, florfenicol; GEN, gentamicin; STR, streptomycin; SXT, trimethoprim/sulfamethoxazole; TET,
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distribution of AMR indices was seen for the 48 isolates from most
animals; the exception being pig ‘E’, from which isolates were
heavily skewed towards low AMR indices, with a high density
achieving an AMR index of one.
Throughput comparison analysis
It was estimated that the human technician would take 30 days to
process these samples compared with 9 days for a robot-assisted
technician (Figure S3). It is important to state that the robots were
not in continuous use during this workflow, meaning there was
time where they could also have been utilized for other tasks.
Discussion
The impetus to transition microbiology from a manual-labour-cen-
tric profession to one embracing automation is nothing novel.
Automation offers the same advantage it has provided industry
for decades; the augmentation of processes to increase efficiency
and throughput; and this statement holds true for the application
of the RASP platform to a conventional microbiology workflow.
Typically, several technicians would be required in the manual
workflow depicted in Figure S3 to prevent the occurrence of issues
such as fatigue, and even still it is unlikely that optimal pace and
quality of work would be maintained for the entirety of the work-
flow; a problem to which the robot is immune. The utilization of
robotics instead allows staff to be diverted from monotonous and
error-prone tasks to more cognitively intensive ones such as data
analysis and project management.21,22 These increases to
throughput are only significant, however, if the solution is finan-
cially viable. It is therefore important to note that the improve-
ment in processing efficiency is just one of several ways by which
automation alleviates sample-processing costs; savings are also
seen on materials and reagents as a result of the transition to
liquid-based methodologies (90% estimated cost reduction).
In consideration of the initial financial outlay of purchasing the
RASP platform (400 000 AUD; equivalent to approximately 300 000
USD or 260 000 EUR), we determined that approximately 9000
samples would need to be processed for the above savings
to equate to this initial cost. The incorporation of robotics into the
routine microbiological assays described in this study is the
technological leap required to elevate the standard of future One
Health AMR surveillance.
Figure 4. Antimicrobial resistance indexing scheme applied to 239 porcine E. coli isolates (48 from pigs A, B C and E and 47 from pig D) using the fol-
lowing antimicrobial risk weightings (w): ampicillin (w = 1), ceftiofur (w = 3), ciprofloxacin (w = 4), gentamicin (w = 2), tetracycline (w = 1) and trimetho-
prim/sulfamethoxazole (w = 2). Colours are representative of the highest weighted resistance present for an isolate. This figure appears in colour in
the online version of JAC and in black and white in the print version of JAC.
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and BD PhoenixTM) do offer the
automation of isolation, identification or AST, in comparison with
RASP they utilize largely inflexible (in terms of pre-determined AST
panels and characterization of a single isolate)23 procedures to
generate this information. To our knowledge, we have developed
the first integrated system—from isolation to AMR profile produc-
tion that meets international guidelines and demonstrated that
the method meets or exceeds the standards required. The
Freedom EVO microbiology robot and by association the RASP
protocol described here utilize broth microdilution testing and
MALDI-TOF integration (both gold-standard microbiological proce-
dures) to capitalize on the higher throughput and resolution of
data offered by its liquid-adapted methods.
AST completed by the robot was comparable to human-gener-
ated data with similar patterns of MIC variance observed. AST in its
current format is highly variable as can be seen by the wide range
of MIC values acceptable for highly tested ATCC control strains.11
This phenomenon was well depicted in Experiment A, where under
well-controlled, faithfully replicated conditions, MIC results from
replicates of the same isolate spanning two or three doubling dilu-
tions were commonly observed. The symmetry of MIC distributions
between raters in these instances suggests that the source of this
variation is biological in nature, due perhaps to phenomena such
as isolates expelling their plasmid, delayed expression of AMR
genes or natural assay variations, as opposed to a technical failure
by either rater.
Due to the restrictions of conventional methods considered
above, most surveys will collect information for approximately 200
isolates per year per country, which limits the inferences that can
be drawn. For example, with respect to the ability to detect early
emergence of resistance to a key drug, a simple application of bi-
nomial probability (expressed as: P(X > 0) j XBin(200, 0.0001))
demonstrates that a survey relying on 200 isolates has a probabil-
ity of only 1.98% of detecting any positives if only 0.01% of isolates
in the population have the resistance trait of interest. This calcula-
tion substantially underestimates the true number of isolates
required during surveillance because reliance on a multi-staged
sampling design (selection of herds, then animals, then isolates) is
essential and carries a cost in accuracy created by the design ef-
fect.24 The AMR indexing experiment included in this study sup-
ports other data8,25 in confirming that variation of E. coli resistance
profiles within bacterial species from the same host and same
group of animals is commonplace. The high level of resolution
available from RASP for describing resistance in microbial popula-
tions, and its ability to yield an affordable increase in the number
of samples and isolates assessed, was demonstrated in the final
validation experiment in this study by the diversity of AMR profiles.
In this final study only 0.4% (n = 1) of tested isolates had an AMR
index of 13, 1.7% (n = 4) had resistance to gentamicin and 1.3%
(n = 3) had resistance to ceftiofur. There was also a corresponding
variation in the number of AMR profiles for E. coli within a host:
there being from 6–9 distinct variants detected in individuals, and
more would likely be detected with higher sample sizes. With the
availability of RASP there is an unprecedented opportunity to
strengthen the management of AMR by shifting from a focus of in-
terpretation adapted to clinical isolates to one that expressly
accommodates the diversity of resistance in hosts at every level of
organization. Data generated on an expanded scale by RASP
therefore presents an opportunity to provide more meaningful
guidance on antimicrobial stewardship at the farm level through
to national and international policy.
Conclusions
RASP and technologies alike unlock a higher calibre of AMR surveil-
lance by overcoming longstanding constraints to scalability. The
flexibility of RASP permits its application well beyond the scope
demonstrated here, to the diverse range of bacterial landscapes
encountered in the One Health system. This study saw RASP’s
workflow benchmarked against that of a contemporary labora-
tory, where it was demonstrated to be equivalent to an experi-
enced human technician but proved superior in throughput,
endurance and cost. It is critical that microbiology harnesses ro-
botic platforms like RASP if we are to resist the current trajectory of
AMR.
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